valine and Tardive Dyskinesia

valine has been researched along with Tardive Dyskinesia in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	37 (74.00)	24.3611
2020's	13 (26.00)	2.80

Authors

Authors	Studies
Arya, D; Fernandez, HH; Khan, T; Margolius, AJ	1
Alexopoulos, GS; Burke, J; Farahmand, K; Sajatovic, M; Siegert, S	1
Akbar, U; Friedman, JH; Kim, DS	1
McEvoy, JP	3
Khorassani, F; Luther, K; Talreja, O	1
Shah, C	1
Kremens, DE; McEvoy, JP	1
Citrome, LL	1
Citrome, L; Saklad, SR	1
Grigoriadis, DE; He, W; Huang, M; Kudwa, A; Meltzer, HY; Rajagopal, L	1
Bashir, HH; Jankovic, J	1
Burke, J; Jimenez, R; Liang, GS; Lindenmayer, JP; Marder, SR; O'Brien, CF; Siegert, S; Verghese, C	1
Espay, AJ; Gupta, HV; Sharma, VD	1
Burke, J; Factor, SA; Hauser, RA; Jimenez, R; Knesevich, MA; Liang, GS; Marder, SR; O'Brien, CF; Ramirez, PM	1
Birkner, T; Davis, MC; Kalsi, JK; Mathis, MV; Miller, BJ	1
Citrome, L	2
Kim, ES	1
Hauser, RA; Seeberger, LC	1
Bozigian, H; Grigoriadis, DE; Loewen, G; O'Brien, CF; Skor, H; Smith, EB	1
Bozigian, H; Jimenez, R; Loewen, G; Luo, R; O'Brien, CF	1
Burke, J; Correll, CU; Josiassen, RC; Liang, GS; O'Brien, CF	1
Burke, J; Josiassen, RC; Kane, JM; Liang, GS; O'Brien, CF	1
Burke, J; Correll, CU; Kane, JM; Liang, GS; O'Brien, CF	1
Aggarwal, S; Caroff, SN; Yonan, C	1
Müller, T	1
Dietterich, TE; Filmyer, DM; Gillean, J; Josiassen, RC; Shah, SS; Shaughnessy, RA	1
Burke, J; Jimenez, R; Liang, GS; O'Brien, CF; Thai-Cuarto, D	1
Henchcliffe, C; Sarva, H	1
Morrow, T	1
Nicewonder, JA; Peckham, AM	1
Jankovic, J; Niemann, N	1
Finn, LA; Hussar, DA	1
Baker, DE; Kim, AP; Levien, TL	1
Correll, CU; Kane, JM; Pigato, G; Solmi, M	1
Agboola, F; Atlas, SJ; Curfman, G	1
Stahl, SM	1
Estevez-Fraga, C; López-Sendón Moreno, JL; Zeun, P	1
Skaff, R	1
Burke, J; Calabrese, JR; Farahmand, K; McIntyre, RS; Nierenberg, AA; Siegert, S; Yonan, C	1
Correll, CU; Cutler, AJ; Kane, JM; Liang, GS; McEvoy, JP; O'Brien, CF	1
Comella, C; Witek, N	1
Addington, D; Barnes, TRE; Carson, A; Edwards, M; Gardner, D; Martino, D; Morgante, F; Poole, N; Pringsheim, T; Remington, G; Ricciardi, L	1
Limandri, BJ	1
Correll, CU; Cutler, AJ; Kane, JM; Liang, GS; O'Brien, CF; Sajatovic, M; Stacy, M	1
Meyer, JM	1
Barquero, N	1

Reviews

20 review(s) available for valine and Tardive Dyskinesia

Article	Year
Tardive Dyskinesia: Treatment Update. Current neurology and neuroscience reports, 2019, 08-16, Volume: 19, Issue:9 Topics: Antipsychotic Agents; Dopamine Antagonists; Drug-Related Side Effects and Adverse Reactions; Humans; Quality of Life; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
FDA-Approved Medications to Treat Tardive Dyskinesia. The Journal of clinical psychiatry, 2019, 12-17, Volume: 81, Issue:1 Topics: Humans; Medication Adherence; Practice Guidelines as Topic; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, Jan-24, Volume: 77, Issue:3 Topics: Humans; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2020
Treatment of Tardive Dyskinesia. Neurologic clinics, 2020, Volume: 38, Issue:2 Topics: Antipsychotic Agents; Botulinum Toxins; Deep Brain Stimulation; Electroconvulsive Therapy; Humans; Muscarinic Antagonists; Neuromuscular Agents; Tardive Dyskinesia; Tetrabenazine; Trihexyphenidyl; Valine; Vesicular Monoamine Transport Proteins	2020
Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International journal of clinical practice, 2017, Volume: 71, Issue:7 Topics: Central Nervous System Agents; Humans; Numbers Needed To Treat; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2017
Valbenazine: First Global Approval. Drugs, 2017, Volume: 77, Issue:10 Topics: Adult; Clinical Trials as Topic; Drug Approval; Humans; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2017
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review. Journal of comparative effectiveness research, 2018, Volume: 7, Issue:2 Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Clinical Trials as Topic; Drug Administration Schedule; Humans; Research Design; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Valbenazine for the treatment of tardive dyskinesia. Expert review of neurotherapeutics, 2017, Volume: 17, Issue:12 Topics: Adrenergic Uptake Inhibitors; Humans; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Valbenazine as the first and only approved treatment for adults with tardive dyskinesia. Expert review of clinical pharmacology, 2018, Volume: 11, Issue:3 Topics: Adult; Animals; Antipsychotic Agents; Dopamine; Drug Approval; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications. Journal of pharmacy practice, 2019, Volume: 32, Issue:4 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Drug Labeling; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs, 2018, Volume: 78, Issue:5 Topics: Antipsychotic Agents; Drug Approval; Humans; Huntington Disease; Tardive Dyskinesia; Tetrabenazine; Tourette Syndrome; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2018
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert review of neurotherapeutics, 2018, Volume: 18, Issue:4 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4 Topics: Drug Approval; Humans; Practice Guidelines as Topic; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug design, development and therapy, 2018, Volume: 12 Topics: Antipsychotic Agents; Humans; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Effectiveness and Value of 2 Novel Treatments for Tardive Dyskinesia. JAMA internal medicine, 2018, 08-01, Volume: 178, Issue:8 Topics: Humans; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2018
Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS spectrums, 2018, Volume: 23, Issue:4 Topics: Adrenergic Uptake Inhibitors; Animals; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2018
Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly. Drugs & aging, 2018, Volume: 35, Issue:11 Topics: Aged; Dementia; Dyskinesia, Drug-Induced; Humans; Parkinsonian Disorders; Risk Factors; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Treatment Recommendations for Tardive Dyskinesia. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2019, Volume: 64, Issue:6 Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Humans; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS spectrums, 2016, Volume: 21, Issue:S1 Topics: Adrenergic Uptake Inhibitors; Amantadine; Antipsychotic Agents; Clonazepam; Dopamine Agents; Dopamine Antagonists; GABA Modulators; Ginkgo biloba; Humans; Plant Extracts; Risk Factors; Tardive Dyskinesia; Tetrabenazine; Valine	2016
Valbenazine for the treatment of tardive dyskinesia. Drugs of today (Barcelona, Spain : 1998), 2016, Volume: 52, Issue:12 Topics: Animals; Dopamine; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2016

Trials

9 trial(s) available for valine and Tardive Dyskinesia

Article	Year
The effects of valbenazine on tardive dyskinesia in older and younger patients. International journal of geriatric psychiatry, 2020, Volume: 35, Issue:1 Topics: Adult; Age Factors; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2020
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. The American journal of psychiatry, 2017, 05-01, Volume: 174, Issue:5 Topics: Abnormal Involuntary Movement Scale; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2017
Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Healthy Volunteers; Humans; Male; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mood Disorders; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Long Term Adverse Effects; Male; Middle Aged; Mood Disorders; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacology bulletin, 2017, 08-01, Volume: 47, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2017
The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. Journal of affective disorders, 2019, 03-01, Volume: 246 Topics: Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Mood Disorders; Tardive Dyskinesia; Tetrabenazine; Valine	2019
Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study. The Journal of clinical psychiatry, 2018, 12-18, Volume: 80, Issue:1 Topics: Adrenergic Uptake Inhibitors; Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Least-Squares Analysis; Outcome Assessment, Health Care; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference. Movement disorders : official journal of the Movement Disorder Society, 2019, Volume: 34, Issue:8 Topics: Aged; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Minimal Clinically Important Difference; Mood Disorders; Psychotic Disorders; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2019

Other Studies

21 other study(ies) available for valine and Tardive Dyskinesia

Article	Year
Valbenazine-induced parkinsonism. Parkinsonism & related disorders, 2020, Volume: 70 Topics: Adrenergic Uptake Inhibitors; Adult; Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease, Secondary; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Comment on Akbar et al., "Valbenazine-induced parkinsonism". Parkinsonism & related disorders, 2020, Volume: 71 Topics: Antipsychotic Agents; Humans; Parkinsonian Disorders; Tardive Dyskinesia; Tetrabenazine; Valine	2020
Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia. The Journal of clinical psychiatry, 2020, Jan-28, Volume: 81, Issue:1 Topics: Antipsychotic Agents; Diagnosis, Differential; Drug Monitoring; Early Diagnosis; Humans; Membrane Transport Modulators; Mood Disorders; Patient Care; Patient Education as Topic; Psychology; Risk Assessment; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine	2020
Medication Options and Clinical Strategies for Treating Tardive Dyskinesia. The Journal of clinical psychiatry, 2020, Jan-28, Volume: 81, Issue:2 Topics: Drug Monitoring; Humans; Medication Therapy Management; Membrane Transport Modulators; Neurologic Examination; Patient Care Management; Psychiatry; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2020
Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and Treatment. The Journal of clinical psychiatry, 2020, 02-18, Volume: 81, Issue:2 Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Diagnosis, Differential; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Schizophrenia; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. Pharmacology, biochemistry, and behavior, 2020, Volume: 190 Topics: Animals; Antipsychotic Agents; Dopamine; Hippocampus; Locomotion; Male; Mice; Mice, Inbred C57BL; Microdialysis; Nucleus Accumbens; Phencyclidine; Prefrontal Cortex; Serotonin; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
A long-term, open-label study of valbenazine for tardive dyskinesia. CNS spectrums, 2021, Volume: 26, Issue:4 Topics: Adrenergic Uptake Inhibitors; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine	2021
Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence. The Journal of clinical psychiatry, 2020, 09-29, Volume: 81, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Clozapine; Humans; Psychiatry; Serotonin Antagonists; Tardive Dyskinesia; Tetrabenazine; Valine	2020
How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care. The Journal of clinical psychiatry, 2020, 11-03, Volume: 81, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Humans; Outcome Assessment, Health Care; Psychiatry; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2020
Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia. Tremor and other hyperkinetic movements (New York, N.Y.), 2020, 12-16, Volume: 10 Topics: Adrenergic beta-Antagonists; Aged; Aripiprazole; Clonazepam; Deprescriptions; Depressive Disorder; Drug Substitution; GABA Modulators; Humans; Male; Parkinsonian Disorders; Pelvis; Propranolol; Quinolones; Serotonin Agents; Tardive Dyskinesia; Tetrabenazine; Thiophenes; Treatment Failure; Valine	2020
Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia. The New England journal of medicine, 2017, Jun-29, Volume: 376, Issue:26 Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Dopamine; Drug Approval; Humans; Synaptic Transmission; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine; Vesicular Monoamine Transport Proteins	2017
Valbenazine (Ingrezza) for tardive dyskinesia. The Medical letter on drugs and therapeutics, 2017, 05-22, Volume: 59, Issue:1521 Topics: Antipsychotic Agents; Humans; Neurotransmitter Uptake Inhibitors; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2017
Valbenazine for the treatment of tardive dyskinesia. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:12 Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Mental Disorders; Tardive Dyskinesia; Tetrabenazine; Treatment Outcome; Valine; Vesicular Monoamine Transport Proteins	2017
Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine. Drugs in R&D, 2017, Volume: 17, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Chromatography, Liquid; Female; Humans; Huntington Disease; Isomerism; Male; Middle Aged; Tandem Mass Spectrometry; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective. The American journal of case reports, 2017, Nov-08, Volume: 18 Topics: Adrenergic Uptake Inhibitors; Antimanic Agents; Female; Humans; Middle Aged; Tardive Dyskinesia; Tetrabenazine; Valine	2017
Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug safety, 2018, Volume: 41, Issue:4 Topics: Aged; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Heart Rate; Humans; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Two New Drugs for Tardive Dyskinesia Hit the Market. Managed care (Langhorne, Pa.), 2018, Volume: 27, Issue:1 Topics: Antipsychotic Agents; Drug Approval; Humans; Managed Care Programs; Tardive Dyskinesia; Tetrabenazine; United States; United States Food and Drug Administration; Valine	2018
2018 New Drug Update. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2018, Apr-01, Volume: 33, Issue:4 Topics: Aged; Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiparkinson Agents; Benzamides; Benzylamines; Constipation; Drug Approval; Humans; Natriuretic Peptides; Psoriasis; Pyridines; Tardive Dyskinesia; Tetrabenazine; Valine	2018
Valbenazine and Deutetrabenazine as possible treatments for neuroleptic-induced supersensitivity psychosis and antipsychotic dependence. CNS spectrums, 2019, Volume: 24, Issue:4 Topics: Antipsychotic Agents; Dopamine; Humans; Psychotic Disorders; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Valbenazine in the treatment of tardive dyskinesia. Neurodegenerative disease management, 2019, Volume: 9, Issue:2 Topics: Adrenergic Uptake Inhibitors; Dopamine Antagonists; Humans; Tardive Dyskinesia; Tetrabenazine; Valine; Vesicular Monoamine Transport Proteins	2019
Tardive Dyskinesia: New Treatments Available. Journal of psychosocial nursing and mental health services, 2019, May-01, Volume: 57, Issue:5 Topics: Antipsychotic Agents; Chlorpromazine; Drug-Related Side Effects and Adverse Reactions; Humans; Psychiatric Nursing; Tardive Dyskinesia; Tetrabenazine; Valine	2019